Immune-Modified Response Criteria in Solid Tumours

Analyzis of atezolizumab data in clinical trials including NSCLC, mUC, RCC and melanoma patients may inform additional modifications to response evaluation criteria

Read full article (External website)

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply